Dr. Nao Takada focuses primarily on domestic and international patent litigation. Dr. Takada has particularly deep experience representing leading pharmaceutical clients in complex litigation arising out of the Hatch-Waxman Act and the Abbreviated New Drug Application (ANDA) process. She brings to her representations a thorough understanding of the federal regulatory processes governing FDA approval of patented and generic drugs.

Dr. Takada also has extensive experience handling other types of high-stakes disputes in the pharmaceutical and biotechnology industries, including especially product liability litigation. She also has experience with intellectual property licensing and prosecution matters.  She often serves as outside general counsel for a variety of Japanese companies doing business in the United States.

Dr. Takada often works across sovereign borders, particularly in relation to Japan.

Prior to joining Zuber Lawler, Dr. Takada practiced patent litigation at Paul Hastings LLP and other international law firms.

Representative Matters

  • Represented a U.S.-based Fortune 100 pharmaceutical company and a Japan–based international generic pharmaceutical company in ANDA litigation against a global pharmaceutical company pursuant to victory at trail.
  • Represented a Japan-based publically traded brand pharmaceutical company against a U.S.-based generic pharmaceutical company in ANDA litigation pursuant to a favorable settlement.
  • Represented a Japan-based pharmaceutical company against an India-based pharmaceutical company in ANDA litigation pursuant to a favorable settlement.
  • Represented a domestic brand pharmaceutical company against  a domestic generic pharmaceutical company in ANDA litigation pursuant to a favorable settlement.